<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149003</url>
  </required_header>
  <id_info>
    <org_study_id>BBI-DSP7888-201G</org_study_id>
    <nct_id>NCT03149003</nct_id>
  </id_info>
  <brief_title>A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy</brief_title>
  <acronym>WIZARD 201G</acronym>
  <official_title>A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2
      study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with
      recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line
      therapy consisting of surgery and radiation with or without chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 8, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the safety and tolerability of DSP-7888 Dosing Emulsion by assessing dose-limiting toxicities (DLTs)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Part 2: To assess the effect of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone on the Overall Survival of patients with recurrent or progressive GBM following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.Overall survival is defined as the interval between randomization and death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Twelve-month Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Part 2: To assess the effect of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone on the survival rate at 12 months of patients with recurrent or progressive GBM following treatment with first line therapy consisting of surgery and radiation with or without.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Part 2: To assess the effect of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone on the Progression Free Survival (PFS) of patients with recurrent or progressive GBM following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy. Progression-free survival is defined as the interval between randomization and progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-month Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Part 2: To assess the effect of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone on the 6-months PFS of patients with recurrent or progressive GBM following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy. Six-month PFS is defined as the proportion of patients alive at 6 months after randomization and without progressive neoplastic disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Part 2: To assess the effect of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone on the response rate of patients with recurrent or progressive GBM following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy. The response rate is defined as the proportion of patients exhibiting a response (complete response [CR] plus partial response [PR]) based on the Response Assessment in Neuro-Oncology (RANO) criteria as determined by the central radiology body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>24 months</time_frame>
    <description>Part 2: To assess the effect of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone on the duration of response of patients with recurrent or progressive GBM following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy. The duration of response is defined as the interval between first documented oncological response and progression of disease or death from any cause, with response based on the RANO criteria as determined by the central radiology body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse Events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: DSP-7888 Dosing Emulsion plus Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-7888 Dosing Emulsion</intervention_name>
    <description>DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.</description>
    <arm_group_label>Arm 1: DSP-7888 Dosing Emulsion plus Bevacizumab</arm_group_label>
    <other_name>adegramotide and nelatimotide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.</description>
    <arm_group_label>Arm 1: DSP-7888 Dosing Emulsion plus Bevacizumab</arm_group_label>
    <arm_group_label>Arm 2: Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients or their legal representatives must be able to provide written informed
             consent.

          2. Histologically confirmed diagnosis of supratentorial GBM (Grade 4 astrocytoma).

          3. Radiographic evidence of first recurrence or progression of GBM following primary
             therapy consisting of surgery (biopsy or resection) and chemoradiation; patients may
             have undergone a second debulking surgery following initial recurrence or progression.
             Patients whose tumors are O6 methyl guanyl-methyl-transferase (MGMT)
             methylated-promoter negative need not have received chemotherapy in the past to be
             eligible.

          4. Human leukocyte antigen type HLA-A*02:01, HLA-A*02:06, or HLA-A*24:02.

          5. Age ≥18.

          6. KPS score of ≥60.

          7. Serum creatinine value &lt;2X the upper limit of normal (ULN) for the reference
             laboratory.

          8. Alanine aminotransferase/aspartate aminotransferase &lt;3X the ULN and total bilirubin
             &lt;2× the ULN for the reference laboratory.

          9. Men and women of childbearing potential must agree to use a reliable method of
             contraception (oral contraceptives, implantable hormonal contraceptives, or double
             barrier method) or agree to completely refrain from heterosexual intercourse for the
             duration of the study and for 180 days following the last dose of DSP-7888 Dosing
             Emulsion.

         10. Patients must have recovered from the effect of all prior therapy to Grade 2 or less.

         11. Patients must be at least 28 days from any major surgery, and any surgery incisions or
             wounds must be completely healed.

         12. Patients must be at least 12 weeks from the completion of prior radiation therapy (RT)
             in order to discriminate pseudo progression of disease from progression.

         13. Patients must be at least 4 weeks from the completion of prior systemic or
             intracranial chemotherapy.

         14. Patients must stop Novo-TTF treatment one day prior to study therapy (no washout
             period is needed). However, any wounds from TTF must be adequately healed per
             Inclusion Criterion #11.15. For patients who are not receiving therapeutic
             anticoagulation treatment, an international normalized ratio (INR) and a PTT ≤ 1.5 ×
             the ULN; patients who are receiving anticoagulation treatment should be on a stable
             dose.

        16. Patient's left ventricular ejection fraction (LVEF) &gt; 40%. 17. Patient has a resting
        pulse oximetry of 90% or higher.

        Exclusion Criteria:

        Patients with any of the following will be excluded from the study:

          1. Prior therapy with Bev.

          2. Patients with secondary GBM.

          3. Any anti-neoplastic therapy, including RT, for first relapse or recurrence.

          4. Evidence of leptomeningeal spread of tumor or any history, presence, or suspicion of
             metastatic disease extracranially.

          5. Evidence of impending herniation on imaging.

          6. Has known multifocal disease. Multifocal disease is defined as discrete sites of
             disease without contiguous T2/FLAIR abnormality that require distinct radiotherapy
             ports. Satellite lesions that are associated with a contiguous area of T2/FLAIR
             abnormality as the main lesion(s) and that are encompassed within the same
             radiotherapy port as the main lesion(s) are permitted.

          7. Patients with infections that have required treatment with systemic antibiotics within
             7 days of first dose of protocol therapy.

          8. The need for systemic glucocorticoids in doses in excess of 4 mg/day of dexamethasone
             or in comparable doses with other glucocorticoids.

          9. Treatment with any investigational agents within 5 half-lives of the agent in question
             or, if the half life is unknown, within 28 days of enrollment.

         10. Pregnant or lactating females.

         11. Prior history of malignancy within 3 years of enrollment other than basal or squamous
             cell carcinoma of the skin, cervical intra-epithelial neoplasia, in situ carcinoma of
             the breast, or prostate cancer treated with surgery or RT with a prostate specific
             antigen of &lt;0.01 ng/mL.

         12. Patients with active autoimmune diseases within 2 years of enrollment into the study
             including, but not limited to, rheumatoid arthritis, systemic lupus erythematosus,
             systemic sclerosis, Sjogren's syndrome, Wegener's granulomatosis, ulcerative colitis,
             Crohn's disease, myasthenia gravis, Graves' disease, or uveitis except for psoriasis
             not requiring systemic therapy, vitiligo or alopecia areata, or hypothyroidism; if an
             autoimmune condition has been clinically silent for 12 months or greater, the patient
             may be eligible for enrollment.

         13. Patients on immunosuppressive therapies; the use of topical, inhalational,
             ophthalmologic or intra articular glucocorticoids, or the use of physiologic
             replacement doses of glucocorticoids are permitted.

         14. Patients with primary immunodeficiency diseases.

         15. Patients with significant bleeding in the preceding 6 months or with known
             coagulopathies.

         16. History of abdominal fistula, intestinal perforation, or intra-abdominal abscess in
             the preceding 12 months.

         17. Positive serology for human immunodeficiency virus (HIV) infection, active hepatitis
             B*, or untreated hepatitis C; patients who have completed a course of anti-viral
             treatment for hepatitis C are eligible.

             *In cases of negative results for HepB surface antigen with positive HepB core
             antibody, HBV DNA testing is required.

         18. Patient has a medical history of frequent ventricular ectopy, e.g., non-sustained
             ventricular tachycardia (VT).

         19. Significant cardiovascular disease, including New York Hospital Association Class III
             or IV congestive heart failure, myocardial infarction within 6 months of enrollment,
             unstable angina, poorly controlled cardiac arrhythmias, or stroke within the preceding
             6 months.

         20. Any other uncontrolled inter current medical condition, including systemic fungal,
             bacterial, or viral infection; uncontrolled hypertension; diabetes mellitus; or
             chronic obstructive pulmonary disease requiring 2 or more hospitalizations in the
             preceding 12 months.

         21. Any psychiatric condition, substance abuse disorder, or social situation that would
             interfere with a patient's cooperation with the requirements of the study.

         22. Known sensitivity to Bev or any of the components of DSP-7888 Dosing Emulsion.

         23. Patient has a QTcF (QT corrected based on Fridericia's equation) interval &gt; 480 msec
             (CTCAE = Grade 2) or other factors that increase the risk of QT prolongation or
             arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT
             interval syndrome) at screening. (Patients with bundle branch block and a prolonged
             QTc interval should be reviewed by the Medical Monitor for potential inclusion.)

         24. Patient has dyspnea at rest (CTCAE ≥ Grade 3) or has required supplemental oxygen
             within 2 weeks of study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neurosciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD- Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles Neuro-Oncology (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Oncology/ US Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Family Associates, George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont brain tumor center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky / Department of Internal Medicine / Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dent Neurosciences Research Center</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Neuro Science Medical</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/ Neurological Institute of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Academic Medicalcenter Cancer Institute</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mischer Neuroscience Associates/Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Wisconsin Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Hospital</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical and Dental Hospital</name>
      <address>
        <city>Chuo Ku</city>
        <state>Niigata</state>
        <zip>951-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Otemae Chuo-ku</city>
        <state>Osaka</state>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyoto Medical Center</name>
      <address>
        <city>Kyoto</city>
        <zip>612-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Shinjuku-Ku</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamagata University Hospital</name>
      <address>
        <city>Yamagata</city>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul</state>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seocho-gu</city>
        <state>Seoul</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seodaemun-gu</city>
        <state>Seoul</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Yude Road</city>
        <state>Taichung</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Chung-Shan South Road</city>
        <state>Taipei</state>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital LinKou Medical Center</name>
      <address>
        <city>Kuei Shan Hsiang</city>
        <state>Taoyuan Hsien</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma (GBM)</keyword>
  <keyword>Wilms Tumor 1 (WT1)</keyword>
  <keyword>Cancer Vaccines</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Astrocytoma</keyword>
  <keyword>Glioma</keyword>
  <keyword>Brain Cancer</keyword>
  <keyword>Brain Tumor</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

